This is consistent with a recently published study based on the largest cohort by present, in which they found a high mutation rate of EGFR (30.1%), ERBB2 (23.2%), BRAF (16.7%), and MAP2K1 (10.6%) in AIS. This evidence concerns the gene ERBB2 and androgen insensitivity syndrome.